Benzinga·Mar 3·Vandana SinghTheravance Biopharma Crashes 27% After Phase 3 Study FailureTheravance Biopharma shares plummet 27% after ampreloxetine fails Phase 3 trial; company cuts workforce 50% and reduces expenses 60%. TBPHstrategic reviewbiotech
Benzinga··Vandana Singh